Topas Therapeutics GmbH, a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, today announced the successful closing of a € 22 m (~US$ 26 m) Series B financing round. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/topas-therapeutics-raises-eur-22-m-us-26-m-in-series-b-financing-and-appoints-klaus-martin-phd-as-chief-executive-officer-5987